Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
171M
-
Number of holders
-
171
-
Total 13F shares, excl. options
-
127M
-
Shares change
-
-1.94M
-
Total reported value, excl. options
-
$826M
-
Value change
-
-$18.8M
-
Put/Call ratio
-
10.59
-
Number of buys
-
92
-
Number of sells
-
-74
-
Price
-
$6.52
Significant Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) as of Q2 2024
203 filings reported holding RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) has 171 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 127M shares
of 171M outstanding shares and own 74.03% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (27.9M shares), VANGUARD GROUP INC (11.7M shares), BlackRock Inc. (10.5M shares), Casdin Capital, LLC (8.45M shares), Bellevue Group AG (6.38M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.04M shares), STATE STREET CORP (4.25M shares), JPMORGAN CHASE & CO (3.96M shares), Nextech Invest Ltd. (3.85M shares), and NORGES BANK (3.32M shares).
This table shows the top 171 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.